|
Kazia Therapeutics Limited (KZIA) DCF تقييم
AU | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Kazia Therapeutics Limited (KZIA) Bundle
عزز استراتيجيات الاستثمار الخاصة بك مع حاسبة (KZIA) DCF! استكشف البيانات المالية الحقيقية من علاجات كازيا ، وضبط تنبؤات النمو والنفقات ، وتصور على الفور كيف تؤثر هذه التغييرات على القيمة الجوهرية لـ (KZIA).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 9.4 | .0 | .0 | 1.4 | 2.2 | 3.2 | 4.8 | 7.3 | 10.9 |
| Revenue Growth, % | 0 | 1430881.24 | -100 | 2120 | 415755.86 | 50 | 50 | 50 | 50 | 50 |
| EBITDA | -6.9 | -3.2 | -14.6 | -13.8 | -16.6 | -1.9 | -2.8 | -4.2 | -6.3 | -9.4 |
| EBITDA, % | -1047076.53 | -33.68 | -94059236 | -4013885.95 | -1159.71 | -86.74 | -86.74 | -86.74 | -86.74 | -86.74 |
| Depreciation | .7 | .8 | 1.2 | 1.2 | 1.2 | 1.7 | 2.5 | 3.8 | 5.7 | 8.5 |
| Depreciation, % | 102200.19 | 8.33 | 7477680 | 336839.64 | 80.98 | 77.86 | 77.86 | 77.86 | 77.86 | 77.86 |
| EBIT | -7.6 | -4.0 | -15.8 | -15.0 | -17.8 | -1.9 | -2.9 | -4.3 | -6.4 | -9.6 |
| EBIT, % | -1149276.72 | -42.01 | -101536916 | -4350725.59 | -1240.68 | -88.4 | -88.4 | -88.4 | -88.4 | -88.4 |
| Total Cash | 5.4 | 17.1 | 4.6 | 3.3 | 1.0 | 2.0 | 3.0 | 4.6 | 6.8 | 10.3 |
| Total Cash, percent | .8 | .0 | 29.4 | .9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .1 | 1.1 | 1.6 | 2.4 | 3.6 | 5.4 |
| Account Receivables, % | 41.38 | 0 | 204000 | 109.91 | 5.76 | 49.43 | 49.43 | 49.43 | 49.43 | 49.43 |
| Inventories | .0 | -.1 | .0 | -2.4 | .0 | -.4 | -.6 | -1.0 | -1.5 | -2.2 |
| Inventories, % | 0.09425071 | -0.55325 | 0 | -683666.85 | 0 | -20.09 | -20.09 | -20.09 | -20.09 | -20.09 |
| Accounts Payable | 1.1 | 1.2 | .9 | .5 | 2.8 | 1.8 | 2.7 | 4.0 | 6.0 | 9.0 |
| Accounts Payable, % | 159660.7 | 12.47 | 6096000 | 154414.41 | 197.05 | 82.49 | 82.49 | 82.49 | 82.49 | 82.49 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITAT | -7.4 | -3.7 | -15.5 | -14.8 | -17.6 | -1.9 | -2.8 | -4.2 | -6.3 | -9.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5.7 | -2.8 | -14.7 | -11.7 | -16.6 | -1.8 | .3 | .4 | .7 | 1.0 |
| WACC, % | 12.35 | 12.33 | 12.36 | 12.36 | 12.36 | 12.35 | 12.35 | 12.35 | 12.35 | 12.35 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1 | |||||||||
| Terminal Value | 10 | |||||||||
| Present Terminal Value | 6 | |||||||||
| Enterprise Value | 5 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | 2.55 |
What You Will Receive
- Adjustable Forecast Parameters: Modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Market Data: Kazia Therapeutics Limited’s financial data pre-loaded to facilitate your analysis.
- Instant DCF Calculations: The template automatically computes Net Present Value (NPV) and intrinsic value.
- Tailored and Professional Design: A refined Excel model that aligns with your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life KZIA Financials: Pre-filled historical and projected data for Kazia Therapeutics Limited (KZIA).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Kazia’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Kazia’s valuation instantly after making adjustments.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template featuring Kazia Therapeutics Limited's (KZIA) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated outcomes, including Kazia's intrinsic value.
- Step 5: Use the results to make informed investment choices or create detailed reports.
Why Choose This Calculator for Kazia Therapeutics Limited (KZIA)?
- Designed for Experts: A sophisticated tool tailored for analysts, investors, and healthcare consultants.
- Accurate Data: Kazia’s historical and projected financials preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Should Use Kazia Therapeutics Limited (KZIA)?
- Healthcare Students: Explore drug development processes and apply theoretical knowledge to real-world scenarios.
- Researchers: Utilize professional models to enhance studies in oncology and pharmaceutical innovation.
- Investors: Evaluate your investment strategies and analyze potential outcomes for Kazia Therapeutics Limited (KZIA).
- Pharmaceutical Analysts: Optimize your analysis with a customizable financial model tailored for biotech companies.
- Entrepreneurs: Understand how biotech firms like Kazia Therapeutics Limited (KZIA) are assessed in the market.
What the Template Contains
- Historical Data: Includes Kazia Therapeutics Limited’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Kazia Therapeutics Limited’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Kazia Therapeutics Limited’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.